A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy

PURPOSE: Naldemedine, an oral, peripherally acting μ-opioid receptor antagonist approved for the treatment of opioid-induced constipation (OIC), is renally excreted. This subgroup analysis integrated data from 3 Phase 3 trials (COMPOSE-1, COMPOSE-2, COMPOSE-3) to evaluate the safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, Lynn R, Hale, Martin E, Yamada, Tadaaki, Wild, James E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125413/
https://www.ncbi.nlm.nih.gov/pubmed/32280263
http://dx.doi.org/10.2147/JPR.S237833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125413/
https://www.ncbi.nlm.nih.gov/pubmed/32280263
http://dx.doi.org/10.2147/JPR.S237833

Ejemplares similares